Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey.
COVID-19
Neuro-oncology
Tumor board
Virtualization
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
21
05
2021
accepted:
03
06
2021
pubmed:
12
6
2021
medline:
28
7
2021
entrez:
11
6
2021
Statut:
ppublish
Résumé
Neuro-oncology tumor boards (NTBs) hold an established function in cancer care as multidisciplinary tumor boards. However, NTBs predominantly exist at academic and/or specialized centers. In addition to increasing centralization throughout the healthcare system, changes due to the COVID-19 pandemic have arguably resulted in advantages by conducting clinical meetings virtually. We therefore asked about the experience and acceptance of (virtualized) NTBs and their potential benefits. A survey questionnaire was developed and distributed via a web-based platform. Specialized neuro-oncological centers in Germany were identified based on the number of brain tumor cases treated in the respective institution per year. Only one representative per center was invited to participate in the survey. Questions targeted the structure/organization of NTBs as well as changes due to the COVID-19 pandemic. A total of 65/97 institutions participated in the survey (response rate 67%). In the context of the COVID-19 pandemic, regular conventions of NTBs were maintained by the respective centers and multi-specialty participation remained high. NTBs were considered valuable by respondents in achieving the most optimal therapy for the affected patient and in maintaining/encouraging interdisciplinary debate/exchange. The settings of NTBs have been adapted during the pandemic with the increased use of virtual technology. Virtual NTBs were found to be beneficial, yet administrative support is lacking in some places. Virtual implementation of NTBs was feasible and accepted in the centers surveyed. Therefore, successful implementation offers new avenues and may be pursued for networking between centers, thereby increasing coverage of neuro-oncology care.
Identifiants
pubmed: 34115248
doi: 10.1007/s11060-021-03784-w
pii: 10.1007/s11060-021-03784-w
pmc: PMC8192684
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
479-485Informations de copyright
© 2021. The Author(s).
Références
American Society of Clinical O, European Society for Medical O (2006) Asco-esmo consensus statement on quality cancer care. Ann Oncol 17(7):1063–1064
doi: 10.1093/annonc/mdl152
Lamb BW, Sevdalis N, Arora S, Pinto A, Vincent C, Green JS (2011) Teamwork and team decision-making at multidisciplinary cancer conferences: barriers, facilitators, and opportunities for improvement. World J Surg 35(9):1970–1976
doi: 10.1007/s00268-011-1152-1
Wright FC, De Vito C, Langer B, Hunter A, Expert Panel on Multidisciplinary Cancer Conference S (2007) Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer 43(6):1002–1010
doi: 10.1016/j.ejca.2007.01.025
Snyder J, Schultz L, Walbert T (2017) The role of tumor board conferences in neuro-oncology: a nationwide provider survey. J Neurooncol 133(1):1–7
doi: 10.1007/s11060-017-2416-x
Robin AM, Walbert T, Mikkelsen T, Kalkanis SN, Rock J, Lee I, Rosenblum ML (2014) Through the patient’s eyes: the value of a comprehensive brain tumor center. J Neurooncol 119(3):465–472
doi: 10.1007/s11060-014-1494-2
Koshy M, Sher DJ, Spiotto M, Husain Z, Engelhard H, Slavin K, Nicholas MK, Weichselbaum RR, Rusthoven C (2017) Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neurooncol 135(3):529–534
doi: 10.1007/s11060-017-2598-2
Zhu P, Du XL, Zhu JJ, Esquenazi Y (2019) Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the national cancer database. J Neurosurg 132(2):491–502
doi: 10.3171/2018.10.JNS182247
Augestad KM, Lindsetmo RO (2009) Overcoming distance: video-conferencing as a clinical and educational tool among surgeons. World J Surg 33(7):1356–1365
doi: 10.1007/s00268-009-0036-0
Munro AJ, Swartzman S (2013) What is a virtual multidisciplinary team (vMDT)? Br J Cancer 108(12):2433–2441
doi: 10.1038/bjc.2013.231
Keesara S, Jonas A, Schulman K (2020) Covid-19 and health care’s digital revolution. N Engl J Med 382(23):e82
doi: 10.1056/NEJMp2005835
Temesgen ZM, DeSimone DC, Mahmood M, Libertin CR, Varatharaj Palraj BR, Berbari EF (2020) Health care after the COVID-19 pandemic and the influence of telemedicine. Mayo Clin Proc 95(9S):S66–S68
doi: 10.1016/j.mayocp.2020.06.052
Dharmarajan H, Anderson JL, Kim S, Sridharan S, Duvvuri U, Ferris RL, Solari MG, Clump DA 2nd, Skinner HD, Ohr JP, Zandberg DP, Bt B, Hughes MA, Traylor KS, Seethala R, Chiosea SI, Nilsen ML, Johnson JT, Kubik MW (2020) Transition to a virtual multidisciplinary tumor board during the covid-19 pandemic: university of pittsburgh experience. Head Neck 42(6):1310–1316
doi: 10.1002/hed.26195
Pross C, Averdunk LH, Stjepanovic J, Busse R, Geissler A (2017) Health care public reporting utilization—user clusters, web trails, and usage barriers on Germany’s public reporting portal Weisse-Liste. De. BMC Med Inform Decis Mak 17(1):48
doi: 10.1186/s12911-017-0440-6
Emmert M, Hessemer S, Meszmer N, Sander U (2014) Do German hospital report cards have the potential to improve the quality of care? Health Policy 118(3):386–395
doi: 10.1016/j.healthpol.2014.07.006
Field KM, Rosenthal MA, Dimou J, Fleet M, Gibbs P, Drummond K (2010) Communication in and clinician satisfaction with multidisciplinary team meetings in neuro-oncology. J Clin Neurosci 17(9):1130–1135
doi: 10.1016/j.jocn.2010.03.001
Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Stupp R, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN (2019) The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol 21(12):1498–1508
doi: 10.1093/neuonc/noz119
Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven V, Nikkhah G, Frommhold H, Volk B, Schumacher M, Lucking C, Zentner J, Ostertag C (2005) The brain tumor board: lessons to be learned from an interdisciplinary conference. Onkologie 28(1):22–26
pubmed: 15616378
Ameratunga M, Miller D, Ng W, Wada M, Gonzalvo A, Cher L, Gan HK (2018) A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting. J Clin Neurosci 56:127–130
doi: 10.1016/j.jocn.2018.06.032
Barker FG 2nd, Curry WT Jr, Carter BS (2005) Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neuro Oncol 7(1):49–63
doi: 10.1215/S1152851704000146
Aulakh S, DeDeo MR, Free J, Rosenfeld SS, Quinones-Hinojosa A, Paulus A, Manna A, Manochakian R, Chanan-Khan AA, Ailawadhi S (2019) Survival trends in glioblastoma and association with treating facility volume. J Clin Neurosci 68:271–274
doi: 10.1016/j.jocn.2019.04.028
Ajmani GS, James TA, Kantor O, Wang CH, Yao KA (2017) The impact of facility volume on rates of pathologic complete response to neoadjuvant chemotherapy used in breast cancer. Ann Surg Oncol 24(11):3157–3166
doi: 10.1245/s10434-017-5969-1
Wouters MW, Wijnhoven BP, Karim-Kos HE, Blaauwgeers HG, Stassen LP, Steup WH, Tilanus HW, Tollenaar RA (2008) High-volume versus low-volume for esophageal resections for cancer: the essential role of case-mix adjustments based on clinical data. Ann Surg Oncol 15(1):80–87
doi: 10.1245/s10434-007-9673-4
Mohile NA, Blakeley JO, Gatson NTN, Hottinger AF, Lassman AB, Ney DE, Olar A, Schiff D, Shih HA, Strowd R, van den Bent MJ, Ziu M (2020) Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the covid-19 pandemic. Neuro Oncol 22(7):912–917
doi: 10.1093/neuonc/noaa090
Gessler F, Lehmann F, Bösel J, Fuhrer H, Neugebauer H, Wartenberg KE, Wolf S, Bernstock JD, Niesen WD, Schuss P (2020) Triage and allocation of neurocritical care resources during the COVID 19 pandemic—a national survey. Front Neurol 11:609227
doi: 10.3389/fneur.2020.609227
Ramakrishna R, Zadeh G, Sheehan JP, Aghi MK (2020) Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the aans/cns tumor section and society for neuro-oncology. J Neuro-Oncol 147(3):525–529
doi: 10.1007/s11060-020-03488-7
Bernhardt D, Wick W, Weiss SE, Sahgal A, Lo SS, Suh JH, Chang EL, Foote M, Perry J, Meyer B, Vajkoczy P, Wen PY, Straube C, Pigorsch S, Wilkens JJ, Combs SE (2020) Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grade iii and iv gliomas. Neuro Oncol 22(7):928–935
doi: 10.1093/neuonc/noaa113
Daggubati LC, Eichberg DG, Ivan ME, Hanft S, Mansouri A, Komotar RJ, D’Amico RS, Zacharia BE (2020) Telemedicine for outpatient neurosurgical oncology care: lessons learned for the future during the COVID-19 pandemic. World Neurosurg 139:e859–e863
doi: 10.1016/j.wneu.2020.05.140
Coomans MB, Dirven L, Aaronson NK, Baumert BG, Van Den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmstrom A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB (2019) Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? Neuro Oncol 21(11):1447–1457
doi: 10.1093/neuonc/noz118